Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Panagiotis A Konstantinopoulos

Showing results (1-10 of 192) with videos related to

Pageof 20
Sort By:
JAMA Oncology|December 27, 2019
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-ReplyPanagiotis A Konstantinopoulos, Shaveta Vinayak
JAMA|June 7, 2011
Seeing the future of cancer-associated transcription factor drug targetsPanagiotis A Konstantinopoulos, Athanasios G Papavassiliou
JAMA|March 8, 2012
Management of ovarian cancer: a 75-year-old woman who has completed treatmentPanagiotis A Konstantinopoulos, Christopher S Awtrey
The New England Journal of Medicine|July 7, 2009
Rosuvastatin in patients undergoing hemodialysisTheodoros I Kassimatis, Panagiotis A Konstantinopoulos
Hematology/Oncology Clinics of North America|November 5, 2018
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian CancerPanagiotis A Konstantinopoulos, Ursula A Matulonis
Drug Discovery Today|March 15, 2006
Chromatin-modulating agents as epigenetic anticancer drugs--'the die is cast'Panagiotis A Konstantinopoulos, Athanasios G Papavassiliou
Trends in Pharmacological Sciences|December 8, 2006
Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapyPanagiotis A Konstantinopoulos, Athanasios G Papavassiliou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2021
Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?Panagiotis A Konstantinopoulos, Stephen A Cannistra
Journal of the American College of Cardiology|November 11, 2008
Statins in patients with chronic kidney disease: a double-edged sword?Theodoros I Kassimatis, Panagiotis A Konstantinopoulos
Expert Opinion on Investigational Drugs|November 26, 2005
17-AAG: mechanisms of antitumour activityPanagiotis A Konstantinopoulos, Athanasios G Papavassiliou
Pageof 20

Showing results (1-10 of 192) with videos related to

Sort By:
Pageof 20
JAMA Oncology|December 27, 2019
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-ReplyPanagiotis A Konstantinopoulos, Shaveta Vinayak
JAMA|June 7, 2011
Seeing the future of cancer-associated transcription factor drug targetsPanagiotis A Konstantinopoulos, Athanasios G Papavassiliou
JAMA|March 8, 2012
Management of ovarian cancer: a 75-year-old woman who has completed treatmentPanagiotis A Konstantinopoulos, Christopher S Awtrey
The New England Journal of Medicine|July 7, 2009
Rosuvastatin in patients undergoing hemodialysisTheodoros I Kassimatis, Panagiotis A Konstantinopoulos
Hematology/Oncology Clinics of North America|November 5, 2018
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian CancerPanagiotis A Konstantinopoulos, Ursula A Matulonis
Drug Discovery Today|March 15, 2006
Chromatin-modulating agents as epigenetic anticancer drugs--'the die is cast'Panagiotis A Konstantinopoulos, Athanasios G Papavassiliou
Trends in Pharmacological Sciences|December 8, 2006
Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapyPanagiotis A Konstantinopoulos, Athanasios G Papavassiliou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2021
Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?Panagiotis A Konstantinopoulos, Stephen A Cannistra
Journal of the American College of Cardiology|November 11, 2008
Statins in patients with chronic kidney disease: a double-edged sword?Theodoros I Kassimatis, Panagiotis A Konstantinopoulos
Expert Opinion on Investigational Drugs|November 26, 2005
17-AAG: mechanisms of antitumour activityPanagiotis A Konstantinopoulos, Athanasios G Papavassiliou
Pageof 20